Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock Moved Up to “Hold” by Zacks Research

Zacks Research upgraded shares of Pelthos Therapeutics (NYSEAMERICAN:PTHS) from a strong sell rating to a hold rating in a research report report published on Wednesday morning,Zacks reports.

A number of other brokerages have also recently commented on PTHS. Alliance Global Partners restated a “buy” rating on shares of Pelthos Therapeutics in a report on Monday, October 26th. Lake Street Capital decreased their price target on shares of Pelthos Therapeutics from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, October 12th. Finally, Oppenheimer lowered their price target on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating for the company in a research report on Friday, August 14th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Pelthos Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $52.83.

Pelthos Therapeutics Trading Down 8.4%

PTHS opened at $9.30 on Wednesday. The company has a quick ratio of 1.31, a current ratio of 1.98 and a debt-to-equity ratio of 3.40. Pelthos Therapeutics has a 52 week low of $9.02 and a 52 week high of $37.50. The stock has a market cap of $35.62 million, a PE ratio of -0.43 and a beta of 3.41. The business has a 50 day moving average of $20.07 and a 200-day moving average of $23.91.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($6.62) earnings per share for the quarter. The firm had revenue of $15.60 million during the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%. Equities research analysts predict that Pelthos Therapeutics will post -15.22 earnings per share for the current fiscal year.

Institutional Trading of Pelthos Therapeutics

An institutional investor recently raised its stake in Pelthos Therapeutics stock. Pale Fire Capital SE raised its stake in shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 59.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,919 shares of the company’s stock after buying an additional 4,819 shares during the quarter. Pale Fire Capital SE owned about 0.38% of Pelthos Therapeutics worth $271,000 at the end of the most recent quarter. Institutional investors own 77.96% of the company’s stock.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).